These effects are likely the consequences on dying cancer cells following treatments and on the direct action of drugs on immune cells, in relation to BCL-XL functions in BLs,49 as reported for cDCs by targeting the BCL2 family,50 and for CD8+ progenitors with an improved responsiveness to anti-PD1 by Decitabine.51 Here, BCL2L1 is linked to cancer.